Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

As an­ti-in­flam­ma­to­ry space heats up, Pfiz­er spins JAK, TYK2 drugs in­to new start­up

Hav­ing bet heav­i­ly on JAK in­hibitors — putting to­geth­er a port­fo­lio an­chored by Xel­janz and now Cib­in­qo — Pfiz­er is get­ting some help to de­vel­op its next such can­di­date.

But we don’t know who the part­ner is just yet.

In pre­pared re­marks dur­ing Pfiz­er’s Q3 earn­ings call, CEO Al­bert Bourla re­vealed to in­vestors that the com­pa­ny has ex­clu­sive­ly li­censed bre­poc­i­tinib, a Phase II dual JAK/TYK2 in­hibitor, to “a new com­pa­ny formed in col­lab­o­ra­tion with a part­ner that has a proven track record in late-stage in­flam­ma­tion and im­munol­o­gy drug de­vel­op­ment.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.